About Pierre Borczuk, MD

Dr. Pierre Borczuk M.D., is an attending physician at the Massachusetts General Hospital Emergency Department. Dr. Borczuk completed his residency and clinical fellowship in medical studies at MGH after graduating from New York University School of Medicine. Over a period of over ten years, Dr. Borczuk has presented a case based seminar called Interesting Case conference, and he has included hundreds of diagnostic dilemmas as well as therapeutic quandaries. In addition, Dr. Borczuk is a participant in departmental CME courses, as well as the Emergency Department's Quality and Safety Committee.

Departments, Centers, & Programs:

Clinical Interests:

Treats:

Locations

Emergency Medicine**
55 Fruit Street
Boston, MA 02114-2696
617-726-7622
Fax: 617-724-4050

Medical Education

  • MD, New York University
  • Residency, Massachusetts General Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Emergency Medicine, American Board of Emergency Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

Dr. Borczuk's main research interests have centered around neurologic emergencies and clinical resource allocation. He has examined indications for ordering cranial CT scans for patients with head trauma, and Dr. Borczuk has developed a 4 element decision rule that can help the practitioner decide which patients with mild head injuries should undergo neuro-imaging. He was involved in a multidisciplinary group of neurologists, emergency physicians and neuro-radiologists, examining the best way to utilize ED CT and MRI scans in patients presenting with acute neurologic complaints (STOPSTROKE study). Dr. Borczuk is about to undertake a study, named TRANCE, to develop a decision rule to help clinicians at community hospitals decide which patients with mild head trauma findings on CT need to be transferred to a level 1 trauma center. Dr. Borczuk also has  completed a multicenter trial comparing the use of Labetolol versus Nicardipine in patients presenting with hypertensive emergencies.